A
Alcista
Alcista · 25%KVUE
$25.34
Precio del escenario
$18.910
+0.244 (+1.29%)Al cierre
Loading chart…
- Máximo
- 18.945
- Apertura
- 18.740
- Precio medio ponderado por volumen
- 18.86
- Volumen
- 27.69M
- Capitalización
- 35.27B
- Mínimo
- 18.715
- Importe
- 522.22M
- EV/EBITDA, TTM
- 11.79
Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
Análisis de IA of Kenvue Inc (KVUE)
ComprarKenvue Inc is a good buy right now as it is currently priced at $18.91, which is below the analyst price targets of $19 from both UBS and Barclays. The stock has shown a strong upward trend with a 5-day change of +6.84% and a year-to-date change of +9.18%. However, the main risk is its high P/E ratio of 49.26, which indicates that it may be overvalued relative to its earnings.
Recomendaciones de analistas (1)
-0.26% Potencial de caída
Vender
0 Comprar
0 Mantener
1 Vender
Actual: 18.91
Mínimo
17.00
Promedio
18.86
Máximo
23.00
UBS
Neutral
$19
2026-08-11
UBS
2026-08-11
Precio objetivo
$19
Neutral
Barclays
Equal Weight
$19
2026-07-21
Barclays
2026-07-21
Precio objetivo
$19
Equal Weight
UBS
Neutral
$20
2026-07-16
UBS
2026-07-16
Precio objetivo
$20
Neutral
Citi
Neutral
$19
2026-04-15
Citi
2026-04-15
Precio objetivo
$19
Neutral
Barclays
Equal Weight
$18
2026-04-14
Barclays
2026-04-14
Precio objetivo
$18
Equal Weight
Métricas de valoración
El PER previsto actual de Kenvue Inc (KVUE) es 14.73, frente a su media de 5 años de 17.52.
Escenarios de precio de Alphio AI para KVUE
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con KVUE en cartera
Cronología de eventos
Noticias
4.510-17CNBCMarket Volatility Amid Strong Bank Earnings
8.510-16CNBCKimberly-Clark Shareholders Receive Positive News Amid Acquisition Progress
6.510-15CNBCMonthly Meeting Review and Outlook on Portfolio
8.510-13CNBCKimberly-Clark Advances Acquisition of Kenvue
8.010-10FoolTop Dividend Stocks for Long-Term Investors
Preguntas frecuentes sobre KVUE, respondidas por Alphio AI
Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM). It operates in the Consumer Non-Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).
Kenvue Inc is a good buy right now as it is currently priced at $18.91, which is below the analyst price targets of $19 from both UBS and Barclays. The stock has shown a strong upward trend with a 5-day change of +6.84% and a year-to-date change of +9.18%. However, the main risk is its high P/E ratio of 49.26, which indicates that it may be overvalued relative to its earnings.
1 analysts cover KVUE: 0 rate it Buy, 0 Hold and 1 Sell. The average price target is 18.86.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.